Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders
Open Access
- 13 March 2023
- journal article
- research article
- Published by Elsevier in Neuropharmacology
- Vol. 231, 109504
Abstract
No abstract availableKeywords
This publication has 120 references indexed in Scilit:
- Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major DepressionBiological Psychiatry, 2013
- Multiple receptors contribute to the behavioral effects of indoleamine hallucinogensNeuropharmacology, 2011
- Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonistsNeuroscience Letters, 2011
- Glutamate N-methyl-D-aspartate Receptor Antagonists Rapidly Reverse Behavioral and Synaptic Deficits Caused by Chronic Stress ExposureBiological Psychiatry, 2011
- 5-HT1A receptor function in major depressive disorderProgress in Neurobiology, 2009
- Gaddum and LSD: the birth and growth of experimental and clinical neuropharmacology research on 5‐HT in the UKBritish Journal of Pharmacology, 2008
- Identification of a serotonin/glutamate receptor complex implicated in psychosisNature, 2008
- Psilocybin-induced stimulus control in the ratPharmacology Biochemistry and Behavior, 2007
- Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortexProceedings of the National Academy of Sciences, 2007
- Role of Gq protein in behavioral effects of the hallucinogenic drug 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropaneNeuropharmacology, 2007